155 related articles for article (PubMed ID: 37195291)
21. Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group.
Marks LJ; Pei Q; Bush R; Buxton A; Appel B; Kelly KM; Schwartz CL; Friedman DL
Pediatr Blood Cancer; 2018 Dec; 65(12):e27375. PubMed ID: 30277639
[TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
23. Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma.
Pinczés L; Miltényi Z; Illés Á
J Cancer Res Clin Oncol; 2018 May; 144(5):935-943. PubMed ID: 29468437
[TBL] [Abstract][Full Text] [Related]
24. Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group.
Appel BE; Chen L; Buxton A; Wolden SL; Hodgson DC; Nachman JB
Pediatr Blood Cancer; 2012 Dec; 59(7):1284-9. PubMed ID: 22847767
[TBL] [Abstract][Full Text] [Related]
25. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant.
Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I
Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748
[TBL] [Abstract][Full Text] [Related]
26. Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation.
Ozuah NW; Dahmoush HM; Grant FD; Lehmann LE; LaCasce AS; Billett AL; Margossian SP
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28696028
[TBL] [Abstract][Full Text] [Related]
27. Hodgkin Lymphoma in Children and Adolescents of Northern Greece: 25-Year Results and Long-term Follow-up.
Kourti M; Papakonstantinou E; Papagianni A; Arsos G; Ioannidou M; Pantoleon A; Antari V; Palabougiouki M; Kouskouras K; Venizelos I; Κoletsa T; Cheva A; Anastasiou A; Totikidis G; Tragiannidis A; Galli-Tsinopoulou A; Hatzipantelis E
J Pediatr Hematol Oncol; 2023 Aug; 45(6):322-326. PubMed ID: 36716084
[TBL] [Abstract][Full Text] [Related]
28. Retrospective analysis of clinical features and treatment outcomes of children with Hodgkin's Lymphoma treated with different chemotherapy protocols at a tertiary care center in Pakistan.
Mehreen A; Wali RM; Sindhu II; Asad M; Ria S
J Pak Med Assoc; 2019 Sep; 69(9):1266-1272. PubMed ID: 31511710
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of Refractory and Relapsed Hodgkin Lymphoma With Autologous Stem-Cell Transplantation: A Single Institution Experience.
Wali R; Saeed H; Patrus N; Javed S; Khan SJ
J Glob Oncol; 2019 Nov; 5():1-6. PubMed ID: 31756138
[TBL] [Abstract][Full Text] [Related]
30. Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution.
Garfin PM; Link MP; Donaldson SS; Advani RH; Luna-Fineman S; Kharbanda S; Porteus M; Weinberg KI; Agarwal-Hashmi R
Biol Blood Marrow Transplant; 2015 Feb; 21(2):326-34. PubMed ID: 25445024
[TBL] [Abstract][Full Text] [Related]
31. Relapse localization in Danish pediatric patients with Hodgkin lymphoma.
Lundgaard AY; Hjalgrim LL; Dejanovic D; Berthelsen AK; Schomerus E; Wendtland P; Specht L; Maraldo MV
Acta Oncol; 2021 May; 60(5):658-666. PubMed ID: 33710948
[TBL] [Abstract][Full Text] [Related]
32. Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE).
Gorde-Grosjean S; Oberlin O; Leblanc T; Pacquement H; Donadieu J; Lambilliotte A; Schell M; Dommange F; Munzer M; Paillard C; Schmitt C; Lutz P; Edan C; Ansoborlo S; Stephan JL; Michel G; Thomas C; Perel Y; Robert A; Landman-Parker J
Br J Haematol; 2012 Sep; 158(5):649-56. PubMed ID: 22757721
[TBL] [Abstract][Full Text] [Related]
33. A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study.
Horton TM; Drachtman RA; Chen L; Cole PD; McCarten K; Voss S; Guillerman RP; Buxton A; Howard SC; Hogan SM; Sheehan AM; López-Terrada D; Mrazek MD; Agrawal N; Wu MF; Liu H; De Alarcon PA; Trippet TM; Schwartz CL
Br J Haematol; 2015 Jul; 170(1):118-22. PubMed ID: 25833390
[TBL] [Abstract][Full Text] [Related]
34. Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma.
Harker-Murray PD; Drachtman RA; Hodgson DC; Chauvenet AR; Kelly KM; Cole PD
Pediatr Blood Cancer; 2014 Apr; 61(4):579-86. PubMed ID: 24504790
[TBL] [Abstract][Full Text] [Related]
35. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group.
Keller FG; Castellino SM; Chen L; Pei Q; Voss SD; McCarten KM; Senn SL; Buxton AB; Bush R; Constine LS; Schwartz CL
Cancer; 2018 Aug; 124(15):3210-3219. PubMed ID: 29738613
[TBL] [Abstract][Full Text] [Related]
36. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma.
Metzger ML; Weinstein HJ; Hudson MM; Billett AL; Larsen EC; Friedmann A; Howard SC; Donaldson SS; Krasin MJ; Kun LE; Marcus KJ; Yock TI; Tarbell N; Billups CA; Wu J; Link MP
JAMA; 2012 Jun; 307(24):2609-16. PubMed ID: 22735430
[TBL] [Abstract][Full Text] [Related]
37. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
[TBL] [Abstract][Full Text] [Related]
38. Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology.
Márky I; Björk O; Forestier E; Jónsson OG; Perkkiö M; Schmiegelow K; Storm-Mathiesen I; Gustafsson G;
J Pediatr Hematol Oncol; 2004 Sep; 26(9):555-60. PubMed ID: 15342981
[TBL] [Abstract][Full Text] [Related]
39. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962.
Harris RE; Termuhlen AM; Smith LM; Lynch J; Henry MM; Perkins SL; Gross TG; Warkentin P; Vlachos A; Harrison L; Cairo MS
Biol Blood Marrow Transplant; 2011 Feb; 17(2):249-58. PubMed ID: 20637881
[TBL] [Abstract][Full Text] [Related]
40. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
